EP0865434B1 - Compounds and their use to treat infectious diseases - Google Patents

Compounds and their use to treat infectious diseases Download PDF

Info

Publication number
EP0865434B1
EP0865434B1 EP96903481A EP96903481A EP0865434B1 EP 0865434 B1 EP0865434 B1 EP 0865434B1 EP 96903481 A EP96903481 A EP 96903481A EP 96903481 A EP96903481 A EP 96903481A EP 0865434 B1 EP0865434 B1 EP 0865434B1
Authority
EP
European Patent Office
Prior art keywords
compound
salts
nhch
cni
compounds
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
EP96903481A
Other languages
German (de)
English (en)
French (fr)
Other versions
EP0865434A4 (enrdf_load_stackoverflow
EP0865434A1 (en
Inventor
Michael I. Bukrinsky
Anthony Cerami
Peter Ulrich
Bradley J. Berger
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Picower Institute for Medical Research
Original Assignee
Picower Institute for Medical Research
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US08/369,830 external-priority patent/US5574040A/en
Application filed by Picower Institute for Medical Research filed Critical Picower Institute for Medical Research
Publication of EP0865434A4 publication Critical patent/EP0865434A4/xx
Publication of EP0865434A1 publication Critical patent/EP0865434A1/en
Application granted granted Critical
Publication of EP0865434B1 publication Critical patent/EP0865434B1/en
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/46—Two or more oxygen, sulphur or nitrogen atoms
    • C07D239/48—Two nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/16—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
    • C07C279/20—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups containing any of the groups, X being a hetero atom, Y being any atom, e.g. acylguanidines
    • C07C279/24—Y being a hetero atom
    • C07C279/26—X and Y being nitrogen atoms, i.e. biguanides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D251/00—Heterocyclic compounds containing 1,3,5-triazine rings
    • C07D251/02—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings
    • C07D251/12—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D251/26—Heterocyclic compounds containing 1,3,5-triazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hetero atoms directly attached to ring carbon atoms
    • C07D251/40—Nitrogen atoms
    • C07D251/48—Two nitrogen atoms
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • the field of the present invention concerns compounds that react with specific sequences in proteins.
  • the present invention more particularly concerns a class of compounds that react, under physiologic conditions, with proteins having adjacent or neighboring lysines.
  • the compounds of the invention can be used to label specifically such proteins for research purposes and to disrupt their function for pharmacologic purposes.
  • the compounds of the invention can also be used to treat infectious diseases such as HIV infection and malaria.
  • nuclear localization signal In eukaryotic cells all proteins are made in the cytoplasm, which is outside of the nucleus. In general, those proteins larger than 40 kD that are specifically localized in the nucleus of the cell must be actively imported into the nucleus through the nuclear membrane from the cytoplasm via an ATP-dependent mechanism that is independent of cell division.
  • the proteins, and other objects, that are imported have a nuclear localization signal (NLS), usually located within the NH 2 terminal segment of the protein.
  • the primary structure, i.e., the linear sequence, of the NLS most frequently contains consecutive lysines, the N ⁇ moieties of which presumably closely approach one another, i.e., they are neighbors.
  • certain functional NLS peptides lack consecutive lysines.
  • the secondary and tertiary D structure of these so called “bipartite" NLS peptides gives rise to neighboring N' moieties, which may be important for their activity.
  • a receptor for the NLS sequence has been recently described in a Xenopus system. Görlich, D., 1994, Cell 79:767. It is a cytoplasmic 60 kDa protein which is homologous with previously described proteins of unknown function, SRP1p of yeast, Yano, R., et al., 1992, Mol.Cell.Biol. 12:5640, and Rch1 of mammals, Cuomo C.A., 1994, Proc.Natl.Acad.Sci. 91:6156.
  • Nuclear localization has been inhibited by lectins (e.g., wheat germ agglutinin (WGA)) that bind to the O-linked glycoproteins associated with nuclear localization.
  • WGA wheat germ agglutinin
  • the nuclear localization process which also depends upon the hydrolysis of GTP, is blocked by a non-hydrolyzable analog of GTP, e.g., ( ⁇ -S)GTP, Melchior, F., 1993, J.Cell Biol. 123:1649.
  • HIV-1 is a retrovirus
  • lentiviruses must be distinguished from viruses of the oncoretrovirus group, which are not associated with progressive fatal infection.
  • lentiviruses replicate in non-proliferating cells, e.g., terminally differentiated macrophages, Weinberg, J.B., 1991, J.Exp. Med. 172:1477-82, while onco-retroviruses, do not. Humphries, E.H., & Temin, H.M., 1974, J.Virol. 14:531-46.
  • lentiviruses are able to maintain themselves in a non-integrated, extrachromosomal form in resting T-cells.
  • the productive infection of a cell by a retroviruses involves the steps of penetration into the cell, synthesis of a DNA genome from the RNA genetic material in the virion and insertion of the DNA genome into a chromosome of the host, thereby forming a provirus.
  • Both lenti- and oncoretroviruses gain access to the host cell's nucleus during mitosis when the nuclear membrane dissolves.
  • the lentiviruses are also able to cross the nuclear membrane because viral proteins containing nuclear localization sequences are associated with the viral nucleoprotein complex.
  • the productive infection of terminally differentiated macrophages located in the central nervous system is thought to be responsible for the dementia associated with AIDS. Keonig, S., et al., 1986, Science 233:1089; Wiley, C.A. et al., 1986, Proc. Natl. Acad. Sci. 83:7089-93; Price, R.W., et al., 1988, Science 239:586-92.
  • the infection of terminally differentiated macrophages in the lymphoid system is known to cause aberrant cytokine production.
  • the wasting syndrome associated with HIV-1 also known as "slim" disease, is believed to be a pathological process that is independent of the loss of CD 4 -T-cells. Rather the pathobiology of the wasting is closely related to the pathobiology of cachexia in chronic inflammatory and malignant diseases. Weiss, R. A., 1993, Science 260:1273. For these reasons, the inhibition on HIV-1 infection of macrophages and other non-dividing cells is understood to represent a highly desired modality in the treatment of HIV-1 infection, especially for patients wherein dementia or cachexia dominate the clinical picture.
  • Macrophages play an important role in the transmission of HIV as well.
  • macrophages and cells of the macrophage lineage i.e. dendritic cells
  • Direct cell-to-cell transmission of the virus may constitute the major route by which infection spreads during the early stages of the disease, after resolution of the initial viremia.
  • macrophage-tropic strains of HIV-1 predominate in the early stages of infection.
  • the infection of macrophages is particularly important during the development of a chronic infective state of the host in a newly infected subject.
  • macrophages are the HIV-susceptible cell type most readily passed during sexual intercourse from an HIV-infected individual into the circulation of an uninfected individual.
  • the matrix protein (MA or p17) nuclear importation activity is clearly due to the presence of a trilysyl-containing NLS sequence.
  • a second protein subserving the function of nuclear entry, the vpr protein does not contain an identifiable NLS consensus sequence. Emerman, M., et al., 1994, Nature 369:108; Heinzinger, N.K. et al., 1994, Proc. Natl. Acad. Sci. 91:7311. Rather vpr is thought to form a complex with a cellular protein that does possess such an NLS sequence.
  • infectious disease Treatment of an infectious disease with chemicals involves killing or inhibition of growth of the infectious agent, which may include free-living and parasitic organisms.
  • Parasitic diseases are widespread in the animal world where a parasitic organism lives at the expense of a host organism, and causes damage, or kills its host.
  • Humans, domestic pets and livestocks are hosts to a variety of parasites.
  • Parasites do not comprise a single taxonomic group, but are found within the protozoans and metazoans, among other groups.
  • infectious parasitic diseases resemble infectious diseases caused by microbiologicals such as fungi, bacteria and viruses.
  • Malaria remains one of the major health problems in the tropics. It is estimated that 300 million people a year are infected with malaria (World Health Organization, 1990, Malaria pp. 15-27. In Tropical Diseases, Progress in Research 1989-1990, Geneva). Malaria is transmitted by Anopheles mosquitos in endemic areas, and often by blood transfusion in eradicated areas.
  • Malaria in humans is caused by at least four protozoan species of Plasmodium: P. falciparum, P. vivax, P. ovale and P. malariae.
  • the asexual erythrocytic parasite, merozoite is the stage in the life cycle that causes the pathology of malaria with a characteristic pattern of fever, chills and sweats.
  • Anemia, acute renal failure and disturbances in consciousness are often associated with malarial infection.
  • P. falciparum can produce a large number of parasites in blood rapidly, and causes the most morbidity and mortality.
  • Antifolates such as pyrimethamine
  • the aminoquinolines such as chloroquine (4-aminoquinoline) have the digestive vacuoles as their major site of action.
  • quinine Prior to the introduction of chloroquine in the 1940's, quinine was the only effective drug for treatment of malaria.
  • Chloroquine is commonly used to treat acute infections with all four species, but has no effect on relapses of infection by P. vivax or P. ovale.
  • Chloroquine 500 mg weekly
  • Chloroquine resistance is widespread and will continue to appear in new areas. Due to the possibility of resistance, the presence of parasites in blood (i.e., parasitemia) is followed closely during treatment, and alternative drugs instituted if indicated. The decision on drug regimen will depend on the origin of the infection.
  • Combination therapy such as quinine and Fansidar (pyrimethamine and sulfadoxine), is applied to treat chloroquine-resistant P. falciparum. Because of the presence of multidrug resistant P. falciparum in many parts of the world, prevention of malaria by chemoprophylaxis with currently available drugs is not always effective.
  • US 4,051,256 relates to N,N'-R 1 ,R 2 -disubstituted guanidines as anti-rhinoviral agents.
  • US 3,908,013 relates to pharmaceutical compositions having vasoconstrictive activity, comprising N-(3'-acetylphenyl)guanidine.
  • FR-A-2 113 916 relates to pharmaceutical compositions having vasoconstrictive activity, comprising N-(4'-acetylphenyl)guanidine.
  • WO 95/19767 discloses N-(3,5-diacetyl-phenyl) guanidine and N-(3,5-diacetlyphenyl) biguanide as synthesis intermediates.
  • the invention involves a class of aryl alkyl carbonyl compounds as defined in claim 1 and dependent claims, particularly, divalent aryl carbonyl moieties N-linked through the arene to a nitrogen-containing heterocyclic functionality, e.g., an acetyl or propanoyl substituted aniline moiety N-linked to a pyrimidinium, pyrimidine or triazine moiety.
  • the invention further encompasses methods of using the compounds of the invention as defined in claims 17 and 18 to form tandem Schiff bases in proteins having neighboring N ⁇ moieties of lysine residues.
  • neighboring N ⁇ moieties are two N ⁇ moieties of a protein that approach each other as close as the carbonyls of the arylene bis (methyl carbonyl) compounds of the invention, when the protein is in its natured conformation.
  • neighboring, adjacent and juxtaposed are equivalent terms in reference to N 4 moieties and refer to the physical locations of the N ⁇ moieties in the structure of the native protein and not to the positions of the lysines in the linear sequence.
  • the invention further encompasses the use of the compounds as defined in claims 19 and dependent claims for preparing a medicament for inhibiting productive infection by HIV-1 of terminally differentiated (non-dividing cells), particularly macrophages, by inhibition of the importation of the cytoplasmic HIV-1 complex into the nucleus of cell.
  • the invention concerns the direct introduction across the cytoplasm membrane of -a cell of compounds that block such importation.
  • the invention encompasses the use of the above-described compounds to prevent productive infection of terminally differentiated macrophages and resting T-cells in HIV-1 infected subjects.
  • the invention is believed to block the HIV-1 replication by the formation of tandem Schiff bases with neighboring N ⁇ moieties of viral proteins, a consequence of which is that the viral nucleoprotein complex does not pass across the nuclear membrane via interaction with the nuclear pore transport complex and/or other cellular components.
  • the invention further encompasses the use of the compounds of the invention for preparing a medicament for treating or preventing infectious diseases such as those caused by parasites, particularly Plasmodium species that cause malaria.
  • the compounds of the present invention can be synthesized by reacting aniline - to form a compound of formula II, described below, wherein P is 1 - or a diacetyl or dipropanoyl derivative of aniline - to form a compound of formula I or formula II wherein P is 2 - with a chloro derivative of purine, aminomethylpyrimidine, diamino-triazine, or with a cyanoguanidine.
  • the reaction can be performed at 90-100°C in an aqueous solvent in the presence of a mineral acid to yield the corresponding aminophenyl pyridine or triazine.
  • the pyrimidinium can be synthesized from the pyrimidine by reaction with an excess methyl iodide at 40-45°C under reflux conditions in 1:1 acetonitrile/tetrahydrofuran or in a 1:1:2 mixture of dichloromethane/acetonitrile/tetrahydrofuran.
  • the compounds of the invention are bis ketone arylene compounds having a third nitrogenous substituent.
  • the nitrogenous substituent can be further substituted with an aromatic nitrogen-containing heterocyclic compound.
  • a quantitative measurement of the activity of the compounds of the invention to block the replication of HIV-1 in non-dividing cells can be determined by culture of a macrophage-tropic strain of HIV-1 on peripheral blood-derived macrophages.
  • the cells are cultured for 5-6 days prior to infection in a medium consisting of DMEM supplemented with 10% type A/B human serum and 200 U/ml Macrophage Colony Stimulating Factor, with half the medium changed after 3 days, to reach a density of about 10 6 cells per 5 ml well.
  • a macrophage-tropic viral stock may be grown on these cells.
  • the concentration of infectious particles in the stock is estimated by measurement of p24 antigen concentration.
  • the cultures are washed to remove non-adherent virus and the culture is re-fed with medium containing the inhibitor at the desired concentration.
  • the amount of replication of HIV-1 is estimated by an assay of the reverse transcriptase activity or by an assay of the concentration of p24 antigen in the culture medium every 2-3 days throughout the post-infection period.
  • the anti-HIV potency of the candidate drug is measured by comparison of the concentration of reverse transcriptase (RT) or of p24 antigen in the medium of the treated and control cultures at the time of the peak of these values in non-treated control cultures, that is about day 5 or 6 post-infection. Repetition at various levels of inhibitor allows for the calculation of the concentration of inhibitor that achieves 50% inhibition of viral growth, IC 50 .
  • Table I discloses the IC 50 of various inhibitors.
  • the compounds may all be compared for inhibition of HIV replication at a fixed concentration.
  • Table II are compounds that were used at a concentration of 100 nM to inhibit the production of HIV-1 in cultured monocytes infected with HIV-1 10 days prior to assay (10 ng of p24/ 10 6 cells). The production of HIV-1 in each treated culture is reported as percentage of untreated control.
  • Figure 2A presents further results of the use of the most active of the compounds of Table I, Compound No. 2, to block the replication of HIV-1 in purified monocytes, cultured in medium supplemented with monocyte-colony stimulating factor (M-CSF).
  • M-CSF monocyte-colony stimulating factor
  • the cultures were treated with none or between 10 -12 and 10 -6 M Compound No. 2 and, simultaneously with the beginning of treatment, the cells were exposed to the monocyte-tropic strain HIV-1 ADA at about 0.01 TCID 50 /cell (1 ng p24/10 6 cells) for 2 hours. Samples were withdrawn at days 3, 6, 10, 14 and 17 after infection and assayed for reverse transcription activity.
  • Compound No. 2 does not inhibit reverse transcriptase, data not shown.
  • the results show that under these conditions the IC 50 concentrations is between 0.1 and 1.0 nM and that a concentration of between 0.1 ⁇ M and 1.0 ⁇ M completely inhibits the replication of the virus.
  • Figures 2B and 2C show the effects of various concentrations of Compound No. 2 on the production of HIV-1 in monocyte cultures not supplemented with M-CSF.
  • MOI as determined by concentration of p24 antigen was;
  • Figure 2B 8 ng/10 6 cells
  • Figure 2C 0.8 ng/10 6 cells.
  • the inhibition of HIV-1 importation into the nucleus of non-dividing cells can also be directly measured.
  • One suitable method to determine directly the activity of compounds of the invention utilizes a cell line that is susceptible to HIV-1 infection, e.g., MT-4 cells, that is growth arrested by treatment with aphidicolin and exposed to HIV-1. PCR amplification is used to detect double-stranded closed circular HIV-1 genomes, which are formed only after nuclear importation, by selecting primers that bridge the junction point of the genome. For greater detail see Bukrinsky, M.I., et al., 1992, Proc. Natl. Acad. Sci. 89:6580-84.
  • the present invention provides the use of a compound of formula (I) for preparing a medicament for the treatment of HIV-1 infection.
  • the compound to be administered is Compound No. 2.
  • Pharmaceutical compositions suitable for oral, intraperitoneal, and intravenous administration can be used in the practice of the invention.
  • Such pharmaceutical compositions include, by way of non-limiting examples, aqueous solutions of the chloride, bicarbonate, phosphate and acetate salts of Compound No. 2 and pH-buffered mixtures thereof.
  • the chloride salt of compound 2 is herein referred to as CNI-0294.
  • Compound 11 and Compound 15 are also known as CNI-1194 and CNI-1594, respectively.
  • the effective dose of the active ingredient can be determined by methods well known to those skilled in medicinal chemistry and pharmacology.
  • An effective dose is the dose that achieves in the subject's plasma a concentration of the active ingredient that is sufficient to inhibit the replication of HIV-1 in monocyte cultures as described in Section 5.4, supra, but does not lead to cytopathic effects in such cultures.
  • the daily dose and dosing schedule to be given a subject can be determined by those skilled in the art, using the pharmacokinetic constants set forth in Table III below, to achieve a target plasma concentration.
  • the target plasma concentration can be selected by routine pharmacological and clinical investigation methods well-known to those skilled in the art, and can be based on a range of concentrations which encompass the IC 50 calculated for each particular compound. For example, the dose can be adjusted to achieve a range of target plasma concentrations that included the IC 50 for the compounds as shown in Table I above.
  • Pharmacokinetic parameters of the CNI compounds CNI-0294 CNI-0294 CNI-0294 CNI-1194 CNI-1194 CNI-1594 CNI-1894 Route of Injection i.p. i.p.
  • the daily dose and dosing schedule needed to obtain a given target average plasma concentration can be calculated.
  • the results of such calculations for Compound Nos. 2, 11 and 15 are presented in Table IV.
  • the calculated doses of Compound Nos. 2 and 15 are considerably below the toxic levels, as measured by the LD 50 , of these compounds. See, Section 6.4 below.
  • a practicable target plasma concentration of Compound No. 2 ranges from 0.5 nM to 10 nM; for Compound No. 11, a practicable target range 5 is from 25 nM to 100 nM; for compound No. 15, a practicable target range is from 7.5 nM to 50 nM.
  • Subjects who can benefit from the use of the compounds of the invention include all persons infected by HIV-1. More particularly, firstly, those who benefit include those subjects who have or are at risk to develop CNS signs of HIV-1 infection and/or subjects that have developed significant weight loss. Secondly, those who benefit include those who have been recently exposed to HIV-1, but who do not yet have an established chronic infection.
  • the compounds of the present invention can be used especially as agents to treat patients suffering from HIV and can be used as agents to treat patients suffering from other viral infections or chronic diseases that are dependent upon nuclear localization as part of the pathogenic process.
  • the compounds of the invention can also be used to treat or prevent other infectious diseases such as parasitic diseases, and in particular malaria.
  • Such a compound can be administered to a patient either by itself, or in pharmaceutical compositions where it is mixed with suitable carriers or excipient(s).
  • compositions of the present invention in particular, those formulated as solutions, may be administered parenterally, such as by intravenous injection.
  • the compounds can be formulated readily using pharmaceutically acceptable carriers well-known in the art into dosages suitable for oral administration.
  • Such carriers enable the compounds of the invention to be formulated as tablets, pills, capsules, liquids, gels, syrups, slurries, suspensions and the like, for oral ingestion by a patient to be treated.
  • compositions suitable for use in the present invention include compositions wherein the active ingredients are contained in an effective amount to achieve its intended purpose. Determination of the effective amounts is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.
  • compositions may contain suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically.
  • suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the active compounds into preparations which can be used pharmaceutically.
  • the preparations formulated for oral administration may be in the form of tablets, dragees, capsules, or solutions.
  • compositions of the present invention may be manufactured in a manner that is itself known, e.g., by means of conventional mixing, dissolving, granulating, dragee-making, levitating, emulsifying, encapsulating, entrapping or lyophilizing processes.
  • compositions for parenteral administration include aqueous solutions of the active compounds in water-soluble form. Additionally, suspensions of the active compounds may be prepared as appropriate oily injection suspensions. Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes. Aqueous injection suspensions may contain substances which increase the viscosity of the suspension, such as sodium carboxymethyl cellulose, sorbitol, or dextran. Optionally, the suspension may also contain suitable stabilizers or agents which increase the solubility of the compounds to allow for the preparation of highly concentrated solutions.
  • compositions for oral use can be obtained by combining the active compounds with solid excipient, optionally grinding a resulting mixture, and processing the mixture of granules, after adding suitable auxiliaries, if desired, to obtain tablets or dragee cores.
  • suitable excipients are, in particular, fillers such as sugars, including lactose, sucrose, mannitol, or sorbitol; cellulose preparations such as, for example, maize starch, wheat starch, rice starch, potato starch, gelatin, gum tragacanth, methyl cellulose, hydroxypropylmethyl-cellulose, sodium carboxymethylcellulose, and/or polyvinylpyrrolidone (PVP).
  • disintegrating agents may be added, such as the cross-linked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof such as sodium alginate.
  • Dragee cores are provided with suitable coatings.
  • suitable coatings For this purpose, concentrated sugar solutions may be used, which may optionally contain gum arabic, talc, polyvinyl pyrrolidone, carbopol gel, polyethylene glycol, and/or titanium dioxide, lacquer solutions, and suitable organic solvents or solvent mixtures.
  • Dyestuffs or pigments may be added to the tablets or dragee coatings for identification or to characterize different combinations of active compound doses.
  • compositions which can be used orally include push-fit capsules made of gelatin, as well as soft, sealed capsules made of gelatin and a plasticizer, such as glycerol or sorbitol.
  • the push-fit capsules can contain the active ingredients in admixture with filler such as lactose, binders such as starches, and/or lubricants such as talc or magnesium stearate and, optionally, stabilizers.
  • the active compounds may be dissolved or suspended in suitable liquids, such as fatty oils, liquid paraffin, or liquid polyethylene glycols.
  • stabilizers may be added.
  • the compounds of the present invention of formula II, wherein P is 1 or 2 can be used to derivatize a target protein and thereby determine the presence of adjacent N ⁇ -moieties.
  • the test reaction can be conducted in aqueous buffer at mild to moderate alkaline pH, between about 7.2 and 8.0.
  • Specific derivatization of the target protein can be detected by any means that separates protein-bound and free derivatizing compound.
  • the derivatizing compound optionally can be detected by radiolabeling it.
  • the compound can be synthesized using 14 C-methyliodide in place of methyliodide. Alternatively, use can be made of the strong UV absorption or fluorescence of the derivatizing compounds.
  • the target protein is derivatized by a compound of the invention, irreversibly reduced with sodium borohydride or cyanoborohydride and fragmented into peptides by trypsin or the like.
  • the resultant peptides can be compared with the peptides obtained from an unreacted sample of the protein by analysis using any chromatographic or electrophoretic technique that resolves peptides, e.g., reverse phase High Performance Liquid Chromatography (HPLC).
  • HPLC High Performance Liquid Chromatography
  • a positive result i.e., a result that indicates the presence of adjacent N ⁇ -moieties, is one in which a large fraction of each of a limited number, i.e., between 1-4, of peptides of the target protein are derivatized and negligible amounts of other peptides are affected.
  • the above-described protein derivatization technique can be used to determine whether a candidate compound can be used, according to the invention to prevent productive HIV-1 infection of macrophages.
  • a comparison of the activity of a candidate compound and that of Compound No. 2 as derivatizing agents specific for nuclear localization sequences can be made.
  • a compound that derivatizes the same peptides to the same extent as Compound No. 2 can be used to practice the invention.
  • the compounds of the present invention can be used to prevent or treat infectious diseases in animals, including mammals and preferably humans, and these compounds are particularly suited to treatment of parasitic diseases, more particularly, malaria.
  • the invention described herein provides the use of the compounds of the present invention for treatment of infection, including and without limitation, infection with parasites, and for preventing diseases associated with such infection.
  • the compounds can reduce parasitemia when administered to an animal infected with a parasite.
  • Infectious diseases may include without limitation: protozoal diseases such as those caused by Kinetoplastida such as Trypanosoma and Leishmania, by Vaccinonadina such as Giardia, by Trichomonadida such as Dientamoeba and Trichomonas, by Gymnamoebia such as Naegleria and the Amoebida such as Entamoeba and Acanthamoeba , by Sporozoasida such as Babesia and the Coccidiasina such as Isospora , Toxoplasma, Cryptosporidium, Eimeria , Thelleria , and Plasmodium; metazoal diseases such as those caused by the Nematoda (roundworms) such as Ascaris , Toxocara , the hookworms, Strongyloides , the whipworms, the pinworms, Dracunculus, Trichinella , and the filarial worms, and by the
  • the compounds of the invention having anti-infective activity are formed according to formula (I) as described in section 5.1.
  • the compounds of the invention having anti-infective activity can also be formed according to formula II: Amoebida such as Entamoeba and Acanthamoeba, by Sporozoasida such as Babesia and the Coccidiasina such as Isospora, Toxoplasma, Cryptosporidium, Eimeria , Thelleria, and Plasmodium ; metazoal diseases such as those caused by the Nematoda (roundworms) such as Ascaris , Toxocara , the hookworms, Strongyloides , the whipworms, the pinworms, Dracunculus, Trichinella , and the filarial worms, and by the Platyhelminthes (flatworms) such as the Trematoda such as Schistosoma , the blood flukes, liver flukes, intestinal flu
  • the compounds of the invention having anti-infective activity are formed according to formula (I) as described in section 5.1.
  • the compounds of the invention as defined in claim 19 and dependent claims may be used therapeutically against infections with Plasmodium species such as P. falciparum, P. vivax, P. ovale and P. malariae, that cause acute and recurrent malaria in humans.
  • Plasmodium species such as P. falciparum, P. vivax, P. ovale and P. malariae
  • the compounds of the invention are also active against infection by other Plasmodium species, which include P. berghei, P. knowlesi, P. simium, P. cynomolgi bastianelli and P. brasilianum.
  • the compounds may be useful in providing chemoprophylaxis for individuals at risk of infection, such as when travelling in endemic areas.
  • malaria By maintaining in circulation an effective concentration of a compound of the invention, malaria can be prevented by suppressing the pathological stages of infection with Plasmodium species.
  • the compounds of the invention can be effective against 5 various stages of the life cycle of the parasite, including sporozoites and merozoites, as well as dormant, asexual and sexual stages.
  • the compounds of the invention may be active in the blood stream, in erythrocytes, in the liver, or in other tissues where the malaria parasite may reside.
  • the compound of the invention can be used to prevent malaria, or to treat malaria, or to treat infection with Plasmodium species that are resistant to antimalarial drugs, such as, but not limited to, chloroquine and pyrimethamine.
  • antimalarial drugs such as, but not limited to, chloroquine and pyrimethamine.
  • the antimalarial properties of the compounds are not diminished against P . falciparum known to be resistant to chloroquine or pyrimethamine (see section 8 infra).
  • the compounds of the invention may be used preferentially to treat malarial infections arising out of areas that are known or suspected to harbor drug-resistant Plasmodium species.
  • the compounds that possess potent antimalarial activity are arylene bis(methylketone) compounds that contain a charged heterocylic ring such as a pyrimidinium, as in CNI-0294 (see Figure 4A).
  • the antimalarial properties of the compounds of the invention can be analyzed by techniques, assays and experimental animal models well known in the art.
  • the inhibition of growth of Plasmodium falciparum in 5 vitro by the compounds may be assessed by the hypoxanthine-incorporation method (Desjardins et al., 1979, Antimicrob. Ag. Chemother. 16:710-718).
  • the in vitro antiparasitic activities of several exemplary compounds of the invention were assessed by this method, and the results are described in Section 8.
  • the in vivo efficacy of the compounds can also be tested in mouse models in which parasitemia is enumerated following administration of the compound (Ager, A.L. 1984, Rodent malaria models, pp 225-264.
  • the present invention also provides pharmaceutical compositions.
  • Such pharmaceutical compositions comprises a prophylactically or therapeutically effective amount of the compound as defined in claim 8 and dependent claims and a pharmaceutical carrier, such as those described in section 5.4.
  • an effective amount means an amount effective to prevent development of or to alleviate the existing symptoms of the subject being treated. Determination of the effective amounts is well within the capability of those skilled in the art, especially in light of the detailed disclosure provided herein.
  • the effective dose can be estimated initially from in vitro assays.
  • a dose can be formulated in animal models to achieve a circulating range that includes the IC 50 (i.e., the concentration of compound which achieves a half-maximal inhibition of growth of parasite) as determined in the in vitro assay. Such information can be used to more accurately determine useful doses in subjects, for example, humans.
  • the dosage may vary within this range depending upon the dosage form employed and the route of administration.
  • Various delivery systems are known and can be used for administration of the compound, e.g., encapsulation in liposomes.
  • Other methods of administration include but are not limited to intradermal, intramuscular, intraperitoneal, intravenous, subcutaneous, intranasal and oral routes.
  • the invention provides the use of compound as defined in claim 19 and dependent claims for preparing a medicament for preventing or treating malaria.
  • the invention also provides the use of a compound of the invention and an antimalarial drug in the manufacture of a medicament for the prevention or treatment of malaria.
  • antimalarial drugs may include but are not limited to quinine, aminoquinolines (chloroquine and primaquine), pyrimethamine, mefloquine, halofantrine, and artemisinins.
  • adjunct administration of a compound of the invention and an antimalarial drug means that the two are administered either as a mixture or sequentially.
  • the compound may be administered before or after the antimalarial drug, so long as the first administered agent is still providing antimalarial activity in the animal when the second agent is administered. Any of the above-described modes of administration may be used in combination to deliver the compound and the antimalarial drug.
  • a compound of the invention and an antimalarial drug are administered adjunctively as a mixture, they are preferably given in the form of a pharmaceutical composition comprising both agents.
  • a pharmaceutical composition comprising a compound of the invention and an antimalarial drug, together with a pharmaceutically acceptable carrier.
  • FIG. 2 A suspension of Compound No. 11 (2-amino-4-(3,5-diacetylphenyl)amino-6-methylpyrimidine) (0.284 g), was suspended in 1:1 acetonitrile-tetrahydrofuran was treated with methyl iodide (2 mL) and heated at 40-45°C under a reflux condenser for 18 hr. Cooling and filtration gave 0.35 g of 2-amino-4-(3,5-diacetylphenyl)amino-1,6-dimethylpyrimidinium iodide, mp 292°C.
  • 2-Amino-4-(3,5-diacetylphenyl)imino-1,4-dihydro-1,6-dimethylpyrimidine A suspension of 21 g (49.3 mmole) of 2-amino-4-(3,5-diacetylphenyl)amino-1,6-dimethylpyrimidinium iodide (compound No. 2, synthesized as described in section 6.1) in 1:1 methanol/water (750 mL) at 60°C was treated with excess 2N NaOH with cooling to maintain about 60°C.
  • CNI-0294 2-Amino-4-(3,5-diacetylphenyl)amino-1,6-dimethylpyrimidinium chloride (CNI-0294).
  • CNI-0294 is the chloride salt of compound No. 2.
  • the base 2-amino-4-(3,5-diacetylphenyl)imino-1,4-dihydro-1,6-dimethylpyrimidine (14.35 g, 48 mmole) was dissolved in 500 mL of methanol and treated with HCl gas until precipitation appeared complete. Filtration gave 12.8 g of white crystals with a faint yellowish tinge, mp 306.5-307.5°.
  • Compound No. 13 A suspension of 3,5-diacetylaniline (1.95 g) in water (10 mL) was treated with 2-chloro-4,6-diamino-1,3,5-triazine (1.455 g) and concentrated HCl (0.1 mL) and heated at reflux for 20 min. After cooling the hydrochloride of Compound No. 13 separated as a white powder. This was filtered out, dissolved in 60 mL of boiling aqueous 75% methanol and treated with triethylamine (1.5 mL). On cooling, off-white flakes separated. Filtration and drying gave 1.79 g of 2-(3,5-diacetylphenyl)amino-4,6-diamino-1,3,5-triazine, mp 271-2°C.
  • Compound No. 16 A suspension of 3,5-diacetylaniline (0.531 g) in water (10 mL) was treated with 6-chloropurine (0.464 g) and concentrated HCl (0.25 mL) and heated at reflux for 30 min. After cooling the mixture was treated with 6 mL of aqueous 1N KOH. The mixture was stirred for 10 min and the solid was filtered out, washed with water, and dried, to give 0.80 g of 6-[(3,5-diacetylphenyl)amino]purine, mp dec 340-350°C.
  • Compound No. 17 (CNI-1794): A suspension of p-aminoacetophenone (1.35 g) and 2-amino-4-chloro-6-methyl-pyrimidine (1.435 g) in 20 mL water was treated with 0.85 mL cone HCl and heated at reflux for 1 hr. Addition of 20 mL 1N KOH gave a light buff solid, which was filtered out and dried to give 2.28 g 4-(3-acetylphenyl)amino-2-amino-6-methylpyrimidine, mp 194-196 °C. Of this, 1.21 g was treated with methyl iodide (3 mL) in dimethylformamide (15 mL) at room temperature for 42 hr.
  • Compound No. 46 A suspension of 4-phenylamino-2-amino-6-methylpyrimidine, Compound No. 45, (0.25 g) in ethanol (4 mL) was treated with methyl methanesulfonate (0.090 g) and heated at reflux for 5 days. Additional methyl methanesulfonate (0.090 g) was added and the mixture refluxed another 2 days. Concentration and recrystallization from a mixture of methanol, ethyl acetate, and tert-butyl ethyl ether gave 0.10 g of 4-phenylamino-2-amino-1,6-dimethylpyrimidinium methanesulfonate.
  • PBMCs peripheral blood by Ficoll-Hypaque centrifugation and adherence to plastic as described previously. Gartner S.P., et al., 1986, Science 233:215. Briefly, after Ficoll-Hypaque (Pharmacia) separation, PBMCs were washed 4 times with DMEM (the last wash was done at 800 rpm to remove platelets) and resuspended in monocyte culture medium [DMEM supplemented with 1 mM glutamine, 10% heat-inactivated human serum, 1% penicillin+streptomycin mixture (Sigma)] at a density of 6x10 6 cells/ml.
  • DMEM monocyte culture medium
  • PBMCs were purified by Ficoll-Hypaque centrifugation and activated by 10 ⁇ g/ml PHA-P (Sigma) and 20 U/ml recombinant human IL-2 (rhIL-2) in RPMI 1640 supplemented with 10% FBS (HyClone). After 24 h incubation, cells were washed and inoculated with HIV-1 ADA in RPMI 1640 supplemented with 10% FBS. After a 2 h adsorption, free virus was washed away and cells were cultured in RPMI 1640 supplemented with 10% FBS and 20 U/ml rhIL-2. Virus stock and infection.
  • Macrophage-tropic strain HIV-1 ADA was amplified in primary human monocytes and concentrated to produce stock with TCID 50 of about 10 5 /ml.
  • concentration of HIV-1 was determined by immunoassay of viral p24, concentration; using a conversion factor of 1 ng / 200 HIV-1 particles.
  • RT reverse transcriptase
  • 10 ⁇ l of culture supernatant was added to 40 ⁇ l of reaction mixture (final composition was 50 mM Tris-HCl, pH 7.8; 20 mM KCl; 5 mM MgCl 2 ; 1 mM DTT; 0.1% Triton X-100; 0.2 OD/ml polyA; 0.2 OD/ml oligo(dT) 12-18 ; and 40 ⁇ Ci/ml 3 H-dTTP (76 Ci/mmol, DuPont) and incubated 2 hr at 37°C.
  • RT reverse transcriptase
  • cytotoxicity of Compound No. 2 was tested in monocyte cultures by trypan blue exclusion assay or lactate dehydrogenase (LDH) release. By both assays, no cytotoxic effect was observed with concentrations of the compound up to 10 ⁇ M (data not shown).
  • Results presented in Fig. 2 show the effect of various concentrations of Compound 2 on HIV-1 replication in monocytes. From this experiment, we estimate the IC 50 for this compound between 0.1 and 1 nM. Similar and higher concentrations of the compound were also tested on activated PBLs. The anti-viral effect of this compound was much less expressed in these actively dividing cell populations (Fig. 3). No anti-viral effect was detected when cultures of replicating cells were infected at the multiplicity of infection used to infect monocytes.
  • AZT is a drug that is routinely used to treat HIV-1 infected persons. However, two factors are known to diminish the effectiveness of AZT: its toxicity and the emergence of resistant mutant strains of HIV-1. The effects of both of these factors can be reduced by administering a second, synergistic HIV-1-inhibitory drug with AZT.
  • the efficiency of nuclear translocation was estimated by the ratio between the 2-LTR- and pol -specific PCR products, which reflects the portion of 2-LTR circle DNA molecules as a fraction of the entire pool of intracellular HIV-1 DNA.
  • Viral 2-LTR circle DNA is formed exclusively within the nucleus of infected cells and thus is a convenient marker of successful nuclear translocation. Bukrinsky, M.I., 5 1992, Procd.Natl.Acad.Sci. 89:6580-84; Bukrinsky, M.I., 1993, Nature 365:666-669.
  • PCR analysis of HIV-1 DNA Total DNA was extracted from HIV-1-infected cells using the IsoQuick extraction kit (Microprobe Corp., Garden Grove, CA).
  • DNA was then analyzed by PCR using primer pairs that amplify the following sequences: a fragment of HIV-1 (LTR/gag) that is the last one to be synthesized during reverse transcription and therefore represents the pool of full-length viral DNA molecules; a fragment of polymerase gene (po1); a 2-LTR junction region found only in HIV-1 2-LTR circle DNA molecules; or a fragment of the cellular a-tubulin gene. Dilutions of 8E5 cells (containing 1 integrated copy of HIV-1 DNA per genome) into CEM cells were used as standards.
  • Amplification products were transferred to nylon membrane filters and hybridized to 32 P-labeled oligonucleotides corresponding to internal sequences specific for each PCR amplification fragment, followed by exposure to Kodak XAR-5 film or a phosphor screen.
  • Quantitation of PCR Reactions Bands of correct size revealed after hybridization were quantitated with a PhosphorImager (Molecular Dynamics) by measuring the total density (integrated volume) of rectangles enclosing the corresponding product band.
  • Efficiency of nuclear translocation of HIV-1 DNA was estimated by measurement of the amount of 2-LTR circle DNA (N 2-LTR ) relative to total viral DNA (N tot ) in each culture, indexed to the same ratio of appropriate control cultures.
  • Translocation Index ( N 2-LTR /N tot ) / ( C 2-LTR /C tot ) x 100.
  • Results Primary human monocytes were infected with HIV-1 ADA in the presence of 100 nM concentration of Compound No. 2 or without drugs (control). Half the medium was changed every 3 days, and drugs were present throughout the whole experiment. Cell samples were taken at 48 and 96 hours post infection and the Translocation Index, relative to the drug free control was determined. At both time points the Translocation Index was less than 10, indicating there was greater than 90% 5 inhibition of nuclear importation.
  • Standard addition curves for each test compound were constructed by adding increased amounts of drug to mouse or human A + plasma (Long Island Blood Services; Melville, NY). An equal volume of 10 mM tetramethylammonium chloride/10 mM heptane sulfonate/4.2 mM H 3 PO 4 (Buffer A) was added to the plasma sample, which was then loaded onto a washed 1 g cyanopropylsilane (or octadecylsilane for CNI-1894) solid-phase extraction column (Fisher Scientific).
  • the column was washed with 1.0 ml of water and then eluted with 1.0 ml of 10 mM tetramethylammonium chloride/10 mM heptane sulfonate/4.2 mM H 3 PO 4 /95% CH 3 CN/5% H 2 O (Buffer C).
  • the eluted sample was reduced to dryness in a rotary evaporator and resuspended in 1.0 ml Buffer A.
  • the mobile phase used was Buffer A and 10 mM tetramethylammonium chloride/10 mM heptane sulfonate/4.2 mM H 3 PO 4 /75% CH 3 CN/25% H 2 O (Buffer B), with all runs initiated at 10% Buffer B.
  • Buffer B 10 mM tetramethylammonium chloride/10 mM heptane sulfonate/4.2 mM H 3 PO 4 /75% CH 3 CN/25% H 2 O
  • Buffer B 10 mM tetramethylammonium chloride/10 mM heptane sulfonate/4.2 mM H 3 PO 4 /75% CH 3 CN/25% H 2 O
  • Buffer B 10 mM tetramethylammonium chloride/10 mM heptane sulfonate/4.2 mM H 3 PO 4 /75% CH 3 CN/25% H 2 O
  • Buffer B 10 mM tetramethylam
  • the doses of compounds of the invention found to be lethal to 50% of the mice were determined by intraperitoneal injection of groups of five animals with increasing doses of each compound.
  • CNI-0294 was administered from 0, 2, 10, 20, 40, 80, 160, 320, 640, 1280 mg/kg in 0.5 ml of water/HCl;
  • CNI-1594 at 0, 2.4, 5, 10, 20, 40, 80 mg/kg in 0.5 ml of water/HCl;
  • CNI-1794 at 0, 20, 50, 80 mg/kg in 0.5 ml of water/HCl;
  • CNI-1894 at 0, 10, 20, 40, 80, 240, 480, 960 mg/kg in water/HCl. All animals were observed for visible signs of acute or long-term toxicity.
  • CNI-0294 was found to be very well tolerated (see Table VI), with no overt signs of toxicity detectable at doses approaching the LD 50 .
  • the other compounds in the CNI series were designed to allow for structure-function relationships with respect to activity and toxicity.
  • CNI-1194 which differs from CNI-0294 only by the lack of a methyl group on the heterocyclic nitrogen, was also well tolerated, with a high LD 50 (Table VI).
  • CNI-1594 which is similar to CNI-1194 plus the omission of one of the acetyl groups on the benzene rings, was appreciably more lethal (Table VI). This toxicity was immediate, with death occurring in minutes and the animals displaying signs of acute neurotoxicity.
  • CNI-1794 which is identical to CNI-1594 except that the single acetyl group is moved para to the heterocyclic substituent, had an LD 50 identical to that for CNI-1594 (Table VI).
  • CNI-1894 which is similar to CNI-0294 and -1194 but lacks the heterocyclic ring, was also reasonably well tolerated. Animals dosed with large amounts of CNI-1894 died 2-3 days post injection, and showed no sign of any immediate toxicity. Based on the above observation, it is concluded that the presence of the heterocyclic ring in the compounds of the invention plays only a small role in determining toxicity, while the presence of two acetyl groups on the benzene ring is very important. Therefore, a preferred compound of the invention showing low toxicity contains two acetyl groups on the benzene ring.
  • mice Female ND4 Swiss Webster mice (21-24 g) were obtained from Harlan Sprague Dawley (Indianapolis, IN) and randomly placed in groups of five in cages with free access to food and water. Each group of animals received 50 mg/kg of CNI-0294, -1194, or -1894, or 20 mg/kg of CNI-1594 in a volume of 0.5 ml.
  • Compound CNI-0294 was administered intraperitoneally or by oral gavage as a solution in water or a suspension in 10% DMSO/peanut oil.
  • the other CNI compounds were administered intraperitoneally or by oral gavage as a solution in water titrated with sufficient HCl to dissolve the drug.
  • a single group of animals was euthanized by carbon dioxide inhalation and bled by cardiac puncture using heparin as an anticoagulant.
  • the blood from the five mice in the group was pooled and centrifuged at 14000 x g for 10 min.
  • the volume of plasma was measured, and equal volume of Buffer A added, and the mixture extracted and analyzed as described above, except that the dried eluates were resuspended in 200 ⁇ l Buffer A and 100 ⁇ l was injected onto the high performance liquid chromatography (HPLC) system.
  • HPLC high performance liquid chromatography
  • AUC oral/ AUC i.p. A and B represent the zero time intercept of the distribution and elimination phases respectively, and ⁇ and ⁇ the respective slopes of the phases multiplied by 2.303.
  • the t 1/2 ⁇ and t 1/2 ⁇ are calculated half-lives of the drug in each phase (0.693/ ⁇ and 0.693/ ⁇ respectively).
  • the volume of distribution (V D ) was calculated as dose/B, and the total clearance rate (Cl tot ) calculated as ⁇ *V D C max and t max are the maximal plasma concentration and time of this measurement, respectively.
  • each compound in the CNI series had similar pharmacokinetic properties despite the structural differences.
  • the kinetic parameters are summarized in Table III and a typical pattern is shown for CNI-1194 in Figure 5.
  • the drugs were rapidly absorbed, with the maximal plasma concentration reached in 5-15 min, and also had a rapid distribution phase, with a t 1/2 ⁇ of 0.32-0.62 hr. Differences were found to occur in the maximal plasma concentration and parameters related to the elimination phase.
  • CNI-0294 achieved the highest maximal plasma level for a single 50 mg/kg i.p. injection, with 18.76 ⁇ g/ml, and CNI-1894 was very similar with a value of 13.43 ⁇ g/ml.
  • a comparison of CNI-1194 and CNI-1594 implied that the number of acetyl groups had little effect on drug absorption.
  • the values relating to elimination were found to vary, but no clear structural relationship could be discerned. All the compounds, except CNI-1894, were undetectable in plasma after 24 hr and approached the limit of detection after 5-6 hr. Therefore, as a general property, the compounds of the invention are absorbed and eliminated rapidly.
  • a preferred compound of the invention has a methyl substituent on the heterocyclic ring nitrogen at position 1 and possesses enhanced absorption from the peritoneum.
  • CNI-0294 and -1194 were also performed with CNI-0294 and -1194 to evaluate relative bioavailability.
  • CNI-0294 was found to have 6% relative bioavailability and CNI-1194 15%.
  • the maximal plasma level was 0.4 ⁇ g/ml for CNI-0294 and 0.35 ⁇ g/ml for CNI-1194, and the drugs were detectable in plasma for at least 6 hr (see Figure 5).
  • mice Several female ND4 Swiss Webster mice were euthanized by carbon dioxide inhalation and the livers excised and rinsed with ice cold phosphate buffered saline (pH 7.4). The livers were minced, gently homogenized in 50 mM phosphate buffer (pH 7.4) with a Dounce homogenizer, and centrifuged at 9600 x g for 20 min. The post-mitochondrial supernatant was kept, glycerol added to 20%, and frozen at -70°C in 1.0 ml aliquots until used.
  • Control incubations were also performed where drug or post-mitochondrial supernatant was omitted.
  • An incubation using pentamidine was performed to confirm microsomal activity (Berger et al., 1992, Antimicrob. Ag. Chemother. 36:1825-1831). Peaks in the CNI compound incubations which increased over time, and were not present in control samples lacking the enzyme preparation were treated as putative metabolites.
  • mice The toxicity, pharmacokinetics, and metabolism of the novel arylene bis(methylketone) compounds of the invention, and several novel analogues thereof likewise of the invention were examined in mice.
  • a median lethal dose of 587.77 mg/kg CNI-0294 was well tolerated when administered intraperitoneally.
  • Analogues which also had two acetyl groups on the phenyl moiety were also well tolerated, with median lethal doses exceeding 160 mg/kg i.p. All visible toxic reactions appeared to be rather delayed (generally 2-3 days post injection). While no biopsy samples were taken, such a delay would be consistent with organ damage by very high doses these compounds.
  • Both CNI-0294 and -1194 were orally absorbed, with a relative bioavailability of 6 and 15 percent respectively. This latter feature is very favorable for continued development of these compounds as anti-infective agents, particularly as antiviral and antiparasitic agents, and more particularly as anti-retroviral and anti-protozoal agents, and yet particularly as anti-HIV agents and antimalarials.
  • the toxicity, kinetic, and bioavailability data suggest that frequent, high, oral doses of the CNI-0294 can safely maintain therapeutically effective plasma concentration.
  • Metabolism of the drugs was assessed in a mouse liver post-mitochondrial supernatant system, and extensive metabolism was discovered (11.74-65.19% metabolized during, a 60 minute incubation). Examination of plasma samples showed that there was considerable in vivo metabolism, with at least 4-6 metabolites easily detected during the first 3 hours following i.p. administration of the test compounds. The levels of metabolite rapidly exceeded plasma concentrations of the parent compound. The HPLC retention times indicated that the compounds were likely altered in the same positions. In addition, the metabolites, like the parent compounds, appeared to have very rapid plasma kinetics.
  • CNI-0294 was found to have considerable anti-malarial activity (Table VII).
  • the median inhibitory concentration was determined as described above.
  • the median inhibitory concentration (IC 50 ) for CNI-0294 was calculated to be 1.79-4.00 ⁇ M for a series of cloned parasites which have different sensitivities to chloroquine or pyrimethamine (Table VII).
  • the Dd2 clone of P. falciparum which was both chloroquine and pyrimethamine resistant, was utilized to compare the antimalarial activity of the remaining CNI compounds (Table VIII).
  • the median inhibitory concentration was determined as described above.
  • CNI-0294 agreed well with the results in Table VII, and CNI-1194 was found to be approximately 5-fold less active. This difference suggested that the heterocyclic methyl group is required for maximal activity.
  • CNI-1594 had an IC 50 equal to that for CNI-1194 or CNI-4594 demonstrating that loss of one or both of the acetyl groups can have little effect on the antimalarial activity.
  • CNI-1894 was inactive at the highest concentration tested.
  • the antimalarial activity of CNI-0294 in vivo was assessed by infecting female ND4 Swiss Webster mice with 100 ⁇ l of Plasmodium berghei NYU-2 infected mouse erythrocytes (50% parasitemia) by intraperitoneal injection. The animals were subsequently injected intraperitoneally once per day on days 1-4 of the infection with 0.5 ml water or 0.5 ml of 50 mg/kg CNI-0294 in water. Four hours after the final injection, small blood samples were taken from the 5 tail, and thin smears stained with Dif-Quick (Baxter, Miami, FL). The parasitemia of control and treated animals was enumerated by inspection of at least 1000 erythrocytes in each animal.
  • CNI-0294 IC 50 for P. falciparum was in the range achieved for approximately one hr following a single i.p. injection of 50 mg/kg in mice, the compound was also screened in vivo in mice infected with Plasmodium berghei. Utilizing the four day suppression test, where parasitemia is enumerated following four daily injections of the test compound (in this case 50 mg/kg i.p.), CNI-0294 was found to significantly (P ⁇ 0.01) lower the parasitemia by 10-fold ( Figure 9).
  • CNI-0294 was effective against various clones of P. falciparum.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
EP96903481A 1995-01-06 1996-01-05 Compounds and their use to treat infectious diseases Expired - Lifetime EP0865434B1 (en)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US463405 1983-02-07
US08/369,830 US5574040A (en) 1995-01-06 1995-01-06 Pyrimidine compounds and methods of use to derivatize neighboring lysine residues in proteins under physiologic conditions
US369830 1995-01-06
US08/463,405 US5733932A (en) 1995-01-06 1995-06-05 Compounds and methods of use to derivatize neighboring lysine residues in proteins under physiological conditions
PCT/US1996/000486 WO1996020932A1 (en) 1995-01-06 1996-01-05 Compounds and methods of use to treat infectious diseases

Publications (3)

Publication Number Publication Date
EP0865434A4 EP0865434A4 (enrdf_load_stackoverflow) 1998-09-23
EP0865434A1 EP0865434A1 (en) 1998-09-23
EP0865434B1 true EP0865434B1 (en) 2003-12-17

Family

ID=27004718

Family Applications (1)

Application Number Title Priority Date Filing Date
EP96903481A Expired - Lifetime EP0865434B1 (en) 1995-01-06 1996-01-05 Compounds and their use to treat infectious diseases

Country Status (7)

Country Link
US (4) US5733932A (enrdf_load_stackoverflow)
EP (1) EP0865434B1 (enrdf_load_stackoverflow)
AT (1) ATE256667T1 (enrdf_load_stackoverflow)
AU (1) AU715844B2 (enrdf_load_stackoverflow)
CA (1) CA2218561C (enrdf_load_stackoverflow)
DE (1) DE69631158T2 (enrdf_load_stackoverflow)
WO (1) WO1996020932A1 (enrdf_load_stackoverflow)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9224739D0 (en) * 1992-11-26 1993-01-13 Wellcome Found Medicaments
US6297253B1 (en) * 1996-10-15 2001-10-02 The Picower Institute For Medical Research Compounds and methods of use to treat infectious diseases
WO2000040246A1 (en) * 1999-01-08 2000-07-13 University Of Massachusetts Detection of human immunodeficiency virus
US6734192B1 (en) * 1999-08-23 2004-05-11 Mp-1 Inc. Treatment of viral infections
ES2154604B1 (es) * 1999-09-06 2001-11-16 Gonzalez Regueral Valdes Jose Medicacion de uso topico aplicable para el tratamiento de enfermedades producidas por virus, especialmente el herpes simplex de los tipos h sv1 y hsv2
US6906067B2 (en) 1999-12-28 2005-06-14 Bristol-Myers Squibb Company N-heterocyclic inhibitors of TNF-α expression
ES2335265T3 (es) * 1999-12-28 2010-03-24 Pharmacopeia, Inc. Inhibidores de citoquina, especialmente de tnf-alfa.
US20040127502A1 (en) * 2001-01-31 2004-07-01 Synaptic Pharmaceutical Corporation Use of GAL3 antagonist for treatment of depression
US7081470B2 (en) * 2001-01-31 2006-07-25 H. Lundbeck A/S Use of GALR3 receptor antagonists for the treatment of depression and/or anxiety and compounds useful in such methods
TWI329105B (en) 2002-02-01 2010-08-21 Rigel Pharmaceuticals Inc 2,4-pyrimidinediamine compounds and their uses
US6797464B2 (en) * 2002-07-10 2004-09-28 University Of Massachusetts Detection of drug-resistant human immunodeficiency virus
ES2445208T3 (es) * 2002-07-29 2014-02-28 Rigel Pharmaceuticals, Inc. Compuestos de 2,4-pirimidindiamina para uso en métodos para tratar o prevenir enfermedades autoinmunitarias
WO2005012263A1 (en) * 2003-07-24 2005-02-10 Pharmagene Laboratories Limited 5-ht2b receptor antagonists
RS53109B (en) 2003-07-30 2014-06-30 Rigel Pharmaceuticals Inc. 2,4 PIRIMIDINDIAMINE COMPOUNDS FOR USE IN TREATMENT OR PREVENTION OF AUTOIMMUNE DISEASES
ES2380550T3 (es) * 2004-11-24 2012-05-16 Rigel Pharmaceuticals, Inc. Compuestos de espiro-2,4-pirimidindiamina y sus usos
WO2007027238A2 (en) * 2005-05-03 2007-03-08 Rigel Pharmaceuticals, Inc. Jak kinase inhibitors and their uses
US20090215819A1 (en) * 2005-06-02 2009-08-27 Laurence Rahme Anti-infective and immunomodulatory compounds

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3908013A (en) * 1970-09-17 1975-09-23 Armour Pharma Pharmaceutical aromatic guanidine compositions and methods of using same
GB1362389A (en) * 1970-11-10 1974-08-07 Armour Pharma Pharmaceutical preparations containing certain guanidine compounds
US4051256A (en) * 1976-09-19 1977-09-27 Imperial Chemical Industries Limited Guanidine derivatives
DK130584A (da) * 1983-04-08 1984-10-09 Ciba Geigy Ag N-(2-nitrophenyl)-4-amino-pyrimidin-derivater samt deres fremstilling og anvendelse som mikrobicider
GB8510758D0 (en) * 1985-04-27 1985-06-05 Wellcome Found Compounds
JPH0629263B2 (ja) * 1985-10-30 1994-04-20 クミアイ化学工業株式会社 ピリミジン誘導体および農園芸用殺菌剤
US5093525A (en) * 1986-07-10 1992-03-03 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education, Acting For And On Behalf Of The Oregon Health Sciences University N,N'-disubstituted guanidines and their use as excitatory amino acid antagonists
US4782062A (en) * 1987-05-11 1988-11-01 Merck & Co., Inc. 9-(2-hydroxymethyl)cycloalkylmethyl) guanines
US4900813A (en) * 1987-07-02 1990-02-13 Ciba-Geigy Corporation Fiber-reactive azo dyes having a 4,6-diaminopyridine coupling component
PH27460A (en) * 1989-12-28 1993-07-09 Kumiai Chemical Industry Co Pyrimidine derivatives and herbicidal composition containing the same
GB9012592D0 (en) * 1990-06-06 1990-07-25 Smithkline Beecham Intercredit Compounds
DE4120247A1 (de) * 1991-06-19 1992-12-24 Henkel Kgaa Neue tetraaminopyrimidin-derivate und deren verwendung in oxidationsfaerbemitteln
US5599984A (en) * 1994-01-21 1997-02-04 The Picower Institute For Medical Research Guanylhydrazones and their use to treat inflammatory conditions

Also Published As

Publication number Publication date
ATE256667T1 (de) 2004-01-15
EP0865434A4 (enrdf_load_stackoverflow) 1998-09-23
CA2218561C (en) 2009-09-15
AU4755996A (en) 1996-07-24
AU715844B2 (en) 2000-02-10
EP0865434A1 (en) 1998-09-23
US5620983A (en) 1997-04-15
US5840893A (en) 1998-11-24
US5733932A (en) 1998-03-31
DE69631158T2 (de) 2004-08-26
WO1996020932A1 (en) 1996-07-11
DE69631158D1 (de) 2004-01-29
CA2218561A1 (en) 1996-07-11
US5703086A (en) 1997-12-30

Similar Documents

Publication Publication Date Title
EP0865434B1 (en) Compounds and their use to treat infectious diseases
US20100137566A1 (en) Compounds and Methods Used to Treat Infectious Diseases
Sriram et al. Design, synthesis and biological evaluation of novel non-nucleoside HIV-1 reverse transcriptase inhibitors with broad-spectrum chemotherapeutic properties
JP2003519232A (ja) プリン誘導体、その製造法およびその使用
AU8282798A (en) Antioxidant enhancement of therapy for hyperproliferative conditions
US6596720B1 (en) Anti-HIV compositions
Sardarian et al. Pyrimethamine analogs as strong inhibitors of double and quadruple mutants of dihydrofolate reductase in human malaria parasites
CA2276525A1 (en) Substituted bis-acridines and related compounds as ccr5 receptor ligands, anti-inflammatory agents and anti-viral agents
EP0476066B1 (en) 3'-azido-2',3'-dideoxy-5-methylcytidine anti-viral composition
Childs et al. Analogues of N-benzyloxydihydrotriazines: in vitro antimalarial activity against Plasmodium falciparum
US5574040A (en) Pyrimidine compounds and methods of use to derivatize neighboring lysine residues in proteins under physiologic conditions
Thottasseri et al. Targeting Blood‐Stage Malaria: Design, Synthesis, Characterization, In Vitro, and In Silico Evaluation of Pyrrolidinodiazenyl Chalcones
JPH03505579A (ja) ヒト免疫不全ウイルス（ｈｉｖ）のインビボにおける活性の阻害方法
Brossi et al. Antimalarial activity and inhibition of monoamine oxidases A and B by exo‐erythrocytic antimalarials: Optical isomers of primaquine, N‐acylated congeners, primaquine metabolites and 5‐phenoxy‐substituted analogues
US5077279A (en) 3'-azido-2',3'-dideoxy-5-methylcytidine anti-viral composition
Yeo et al. Effects of dual combinations of antifolates with atovaquone or dapsone on nucleotide levels in Plasmodium falciparum
US20160159778A1 (en) Novel ureido derivatives of naphthalenesulfonic acids
US6225307B1 (en) Viral treatment
ZA200701826B (en) Furamate of 4-[[4-[[4-(2-cyanoethenyl)-2,6-dimethylphenyl] amino]-2-pyrimidinyl]amino]benzonitrile
Sriram et al. Aminopyrimidinimino isatin analogues: design and synthesis of novel non-nucleoside HIV-1 reverse transcriptase inhibitors with broad-spectrum anti-microbial properties
US7144874B2 (en) Aryl phosphate derivatives of d4T having activity against resistant HIV strains
Priyadarsini et al. Docking studies, Synthesis, Characterisation of Substituted Benzothiazoles as DHFR inhibitors and Evaluation of their Antitubercular Activities.
US20050113454A1 (en) Anti-viral compounds
EP0186454A2 (en) 6-Purinyl N-(2-chloroethyl) carbamate and thiocarbamate, a process for their preparation and use thereof
HK1014660B (en) 3'-azido-2',3'-dideoxy-5-methylcytidine anti-viral composition

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19971008

A4 Supplementary search report drawn up and despatched

Effective date: 19980526

AK Designated contracting states

Kind code of ref document: A4

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Free format text: LT PAYMENT 971008;LV PAYMENT 971008;SI PAYMENT 971008

17Q First examination report despatched

Effective date: 19991028

GRAH Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOS IGRA

RTI1 Title (correction)

Free format text: COMPOUNDS AND THEIR USE TO TREAT INFECTIOUS DISEASES

GRAS Grant fee paid

Free format text: ORIGINAL CODE: EPIDOSNIGR3

GRAA (expected) grant

Free format text: ORIGINAL CODE: 0009210

AK Designated contracting states

Kind code of ref document: B1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

AX Request for extension of the european patent

Extension state: LT LV SI

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: NL

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20031217

Ref country code: LI

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20031217

Ref country code: CH

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20031217

Ref country code: BE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20031217

Ref country code: AT

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20031217

REG Reference to a national code

Ref country code: GB

Ref legal event code: FG4D

REG Reference to a national code

Ref country code: CH

Ref legal event code: EP

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: LU

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040105

Ref country code: IE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040105

REG Reference to a national code

Ref country code: IE

Ref legal event code: FG4D

REF Corresponds to:

Ref document number: 69631158

Country of ref document: DE

Date of ref document: 20040129

Kind code of ref document: P

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: MC

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040131

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: SE

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040317

Ref country code: GR

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040317

Ref country code: DK

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040317

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: ES

Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT

Effective date: 20040328

LTIE Lt: invalidation of european patent or patent extension

Effective date: 20031217

NLV1 Nl: lapsed or annulled due to failure to fulfill the requirements of art. 29p and 29m of the patents act
REG Reference to a national code

Ref country code: CH

Ref legal event code: PL

REG Reference to a national code

Ref country code: IE

Ref legal event code: MM4A

ET Fr: translation filed
PLBE No opposition filed within time limit

Free format text: ORIGINAL CODE: 0009261

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT

26N No opposition filed

Effective date: 20040920

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: FR

Payment date: 20050222

Year of fee payment: 10

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: GB

Payment date: 20050225

Year of fee payment: 10

Ref country code: DE

Payment date: 20050225

Year of fee payment: 10

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: GB

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060105

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: FR

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060131

PGFP Annual fee paid to national office [announced via postgrant information from national office to epo]

Ref country code: IT

Payment date: 20060131

Year of fee payment: 11

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: DE

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20060801

GBPC Gb: european patent ceased through non-payment of renewal fee

Effective date: 20060105

REG Reference to a national code

Ref country code: FR

Ref legal event code: ST

Effective date: 20060929

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: PT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20040517

PG25 Lapsed in a contracting state [announced via postgrant information from national office to epo]

Ref country code: IT

Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES

Effective date: 20070105